Singapore markets closed

LLY Jan 2026 570.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
263.640.00 (0.00%)
As of 02:32PM EDT. Market open.
Full screen
Previous close263.64
Open263.64
Bid253.05
Ask259.75
Strike570.00
Expiry date2026-01-16
Day's range263.64 - 263.64
Contract rangeN/A
Volume2
Open interest40
  • Yahoo Finance Video

    Eli Lilly's weight loss drug could help sleep apnea patients

    Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith

  • Zacks

    Company News for Apr 18, 2024

    Companies In The Article are: LLY,ADSK,MBLY,USB

  • Zacks

    Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

    Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.